Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Effect of Foscarnet Therapy on Human Immunodeficiency Virus p24 Antigen Levels in AIDS Patients with Cytomegalovirus Retinitis

Mohan M. Reddy, Michael H. Grieco, George F. McKinley, Dennis M. Causey, Charles M. van der Horst, David M. Parenti, Thomas M. Hooton, Roger B. Davis and Mark A. Jacobson
The Journal of Infectious Diseases
Vol. 166, No. 3 (Sep., 1992), pp. 607-610
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30113329
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Effect of Foscarnet Therapy on Human Immunodeficiency Virus p24 Antigen Levels in AIDS Patients with Cytomegalovirus Retinitis
Preview not available

Abstract

Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials. The HIV p24 antigen levels decreased from a baseline value of 199 ± 236 (mean ± SD) and 140 pg/mL (median) to 106 ± 218 and 28 pg/mL after 14 days of foscarnet induction therapy (60 mg/kg every 8 h). During chronic foscarnet maintenance, there was a sustained decrease in mean HIV p24 antigen levels below pre-foscarnet therapy baseline concentrations for a median of 16 weeks after foscarnet induction. These results provide evidence for a sustained clinical antiretroviral effect of chronic foscarnet maintenance therapy, consistent with a recent report that foscarnet-treated AIDS patients live longer than ganciclovir-treated patients.

Page Thumbnails

  • Thumbnail: Page 
607
    607
  • Thumbnail: Page 
608
    608
  • Thumbnail: Page 
609
    609
  • Thumbnail: Page 
610
    610